Provided by Tiger Fintech (Singapore) Pte. Ltd.

Astria Therapeutics Inc

4.04
+0.06001.51%
Post-market: 4.040.00000.00%17:15 EDT
Volume:202.27K
Turnover:816.80K
Market Cap:227.99M
PE:-2.41
High:4.18
Open:3.97
Low:3.93
Close:3.98
Loading ...

Astria Therapeutics Q4 EPS $(0.44) Beats $(0.45) Estimate

Benzinga
·
11 Mar

Press Release: Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Dow Jones
·
11 Mar

TD Cowen Sticks to Its Buy Rating for Astria Therapeutics (ATXS)

TIPRANKS
·
10 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
05 Mar

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Mar

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
05 Mar

Astria Therapeutics Price Target Maintained With a $26.00/Share by Citizens Capital Markets

Dow Jones
·
03 Mar

TD Cowen Remains a Buy on Astria Therapeutics (ATXS)

TIPRANKS
·
02 Mar

Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Feb

Analysts Are Bullish on Top Healthcare Stocks: Vericel (VCEL), Astria Therapeutics (ATXS)

TIPRANKS
·
28 Feb

Astria Therapeutics Initiates Alpha-Orbit Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

THOMSON REUTERS
·
27 Feb

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Business Wire
·
27 Feb

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Feb

Astria Therapeutics' Shares Rise After JMP Securities Initiates Coverage With Outperform Rating

MT Newswires Live
·
01 Feb

Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Jan

Astria Therapeutics Starts Phase 1a Trial of Atopic Dermatitis Treatment

MT Newswires Live
·
23 Jan

Astria initiates Phase 1a Trial of STAR-0310 trial, sees proof of concept in Q3

TIPRANKS
·
23 Jan

Astria Therapeutics Inc - Early Proof-of-Concept Results Expected in Q3 2025

THOMSON REUTERS
·
23 Jan

Astria Therapeutics Announces Initiation of Phase 1a Trial of Star-0310, a Potential Best-in-Class Monoclonal Antibody Ox40 Antagonist for the Treatment of Atopic Dermatitis

THOMSON REUTERS
·
23 Jan

Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and Mediwound (MDWD)

TIPRANKS
·
14 Jan